Fosrenol FDA Approval History
FDA Approved: Yes (First approved October 26, 2004)
Brand name: Fosrenol
Generic name: lanthanum carbonate
Dosage form: Chewable Tablets
Company: Shire Pharmaceuticals Group plc
Treatment for: Hyperphosphatemia of Renal Failure
Fosrenol is a phosphate binder used to reduce high phosphorus levels in end-stage renal disease (ESRD) patients.
Development timeline for Fosrenol
| Date | Article |
|---|---|
| Oct 26, 2004 | Approval Fosrenol Shire Pharmaceuticals Group plc - Treatment for Hyperphosphataemia in ESRD Patients |
| Jul 20, 2004 | Fosrenol: FDA Action Date Extended, US Launch Target Unaffected |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
